Notably, 16.7% of patients in our study with severe or critical COVID-19 exhibited functionally strong neutralizing anti-IFN-α AAbs comparable to the 9–11% prevalence observed in severe cohorts from Spain and Shanghai [13,14,15,16]. This evidence concerns the gene IFNA2 and COVID-19.